Suppr超能文献

化生性乳腺癌的临床特征及总生存预后列线图

Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer.

作者信息

Zheng Caihong, Fu Chengbin, Wen Yahui, Liu Jiameng, Lin Shunguo, Han Hui, Han Zhonghua, Xu Chunsen

机构信息

The Graduate School of Fujian Medical University, Fuzhou, Fujian, China.

Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.

出版信息

Front Oncol. 2023 Mar 2;13:1030124. doi: 10.3389/fonc.2023.1030124. eCollection 2023.

Abstract

BACKGROUND

Metaplastic breast cancer (MBC) is a rare breast tumor and the prognostic factors for survival in patients still remain controversial. This study aims to develop and validate a nomogram to predict the overall survival (OS) of patients with MBC.

METHODS

We searched the Surveillance, Epidemiology, and End Results (SEER) database for data about patients including metaplastic breast cancer and infiltrating ductal carcinoma (IDC) from 2010 to 2018. The survival outcomes of patients between MBC and IDC were analyzed and compared with the Kaplan-Meier (KM) method. MBC patients were randomly allocated to the training set and validation I set by a ratio of eight to two. Meanwhile, the performance of this model was validated again by the validation II set, which consisted of MBC patients from the Union Hospital of Fujian Medical University between 2010 and 2018. The independent prognostic factors were selected by univariate and multivariate Cox regression analyses. The nomogram was constructed to predict individual survival outcomes for MBC patients. The discriminative power, calibration, and clinical effectiveness of the nomogram were evaluated by the concordance index (C-index), the receiver operating characteristic (ROC) curve, and the decision curve analysis (DCA).

RESULTS

MBC had a significantly higher T stage (T2 and above accounting for 75.1% vs 39.9%), fewer infiltrated lymph nodes (N0 accounted for 76.2% vs 67.7%), a lower proportion of ER (22.2% vs 81.2%), PR (13.6% vs 71.4%), and HER-2(6.7% vs 17.7%) positive, radiotherapy(51.6% vs 58.0%) but more chemotherapy(67.5% vs 44.7%), and a higher rate of mastectomy(53.2% vs 36.8%), which was discovered when comparing the clinical baseline data between MBC and IDC. Age at diagnosis, T, N, and M stage, as well as surgery and radiation treatment, were all significant independent prognostic factors for overall survival (OS). In the validation I cohort, the nomogram's C-index (0.769 95% CI 0.710 -0.828) was indicated to be considerably higher than the standard AJCC model's (0.700 95% CI 0.644 -0.756). Nomogram's great predictive capability capacity further was supported by the comparatively high C-index of the validation II sets (0.728 95%CI 0.588-0.869).

CONCLUSIONS

Metaplastic breast cancer is more aggressive, with a worse clinical prognosis than IDC. This nomogram is recommended for patients with MBC, both American and Chinese, which can help clinicians make more accurate individualized survival analyses.

摘要

背景

化生性乳腺癌(MBC)是一种罕见的乳腺肿瘤,患者生存的预后因素仍存在争议。本研究旨在开发并验证一种列线图,以预测MBC患者的总生存期(OS)。

方法

我们在监测、流行病学和最终结果(SEER)数据库中搜索了2010年至2018年期间包括化生性乳腺癌和浸润性导管癌(IDC)患者的数据。采用Kaplan-Meier(KM)方法分析并比较了MBC和IDC患者的生存结局。MBC患者按8:2的比例随机分配到训练集和验证I组。同时,由2010年至2018年福建医科大学附属协和医院的MBC患者组成验证II组,再次验证该模型的性能。通过单因素和多因素Cox回归分析选择独立预后因素。构建列线图以预测MBC患者的个体生存结局。通过一致性指数(C-index)、受试者操作特征(ROC)曲线和决策曲线分析(DCA)评估列线图的鉴别能力、校准度和临床有效性。

结果

与IDC相比,MBC的T分期显著更高(T2及以上占75.1% 对39.9%),浸润淋巴结更少(N0占76.2% 对67.7%),ER(22.2% 对81.2%)、PR(13.6% 对71.4%)和HER-2(6.7% 对17.7%)阳性比例更低,放疗比例(51.6% 对58.0%)更低但化疗比例(67.5% 对44.7%)更高,乳房切除术率更高(53.2% 对36.8%)。诊断年龄、T、N和M分期以及手术和放疗均是总生存期(OS)的显著独立预后因素。在验证I队列中,列线图的C-index(0.769,95%CI 0.710 -0.828)显著高于标准AJCC模型(0.700,95%CI 0.644 -0.756)。验证II组相对较高的C-index(0.728,95%CI 0.588 -0.869)进一步支持了列线图具有强大的预测能力。

结论

化生性乳腺癌比IDC更具侵袭性,临床预后更差。推荐美国和中国的MBC患者使用此列线图,它可帮助临床医生进行更准确的个体化生存分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/eb9560a1c831/fonc-13-1030124-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验